Home > Newsletters > Drug Industry Daily > J&J Submits Supplemental Zytiga Apps as Some Experts Question Early Trial Stoppage
Drug Industry Daily
June 18, 2012 | Vol. 11 No. 119
J&J Submits Supplemental Zytiga Apps as Some Experts Question Early Trial Stoppage
Johnson & Johnson (J&J) has submitted supplemental marketing applications to the FDA and European Medicines Agency (EMA) for its prostate cancer treatment Zytiga for use following failed androgen deprivation therapy but before chemotherapy.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.